Eye On The Prize: For $8.7 Billion, Valeant Will Acquire Bausch & Lomb

As with its Medicis buyout in 2012, Valeant is acquiring another company to serve essentially as a therapeutic division within the specialty pharma the Canadian firm is cobbling together from relentless M&A activity. Buying B&L will increase Valeant’s eye care holdings substantially.